{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:16:26Z","timestamp":1771982186508,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2014,5]]},"abstract":"Background<\/jats:title>Rarely, healthy donors fail adequate peripheral blood stem cell (PBSC<\/jats:styled-content>) mobilization. If the recipient has already received conditioning chemotherapy, this can result in the donor undergoing urgent marrow harvest under general anesthesia. Plerixafor is a novel CXCR<\/jats:styled-content>4 antagonist, licensed for autologous PBSC<\/jats:styled-content> harvest (PBSCH<\/jats:styled-content>) in patients who failed mobilization with granulocyte\u2013colony\u2010stimulating factor (G<\/jats:styled-content>\u2010CSF<\/jats:styled-content>) alone. Experience using plerixafor in healthy allogeneic donors failing G<\/jats:styled-content>\u2010CSF<\/jats:styled-content> mobilization is scarce.<\/jats:p><\/jats:sec>Case Report<\/jats:title>A 65\u2010year\u2010old patient was referred for a reduced\u2010intensity conditioning sibling allograft for relapsed follicular lymphoma. She received fludarabine, melphalan, and alemtuzumab conditioning. Her 68\u2010year\u2010old brother was fully HLA<\/jats:styled-content> matched. PBSCH<\/jats:styled-content> was planned on D<\/jats:styled-content>ay\u2009\u22121 after 4 days of 10\u2009\u03bcg\/kg G<\/jats:styled-content>\u2010CSF<\/jats:styled-content>. D<\/jats:styled-content>ay\u20091 PBSCH<\/jats:styled-content> collected an inadequate number of CD<\/jats:styled-content>34+ 0.35\u2009\u00d7\u2009106<\/jats:sup>\/kg cells. Despite increasing G<\/jats:styled-content>\u2010CSF<\/jats:styled-content> (16\u2009\u03bcg\/kg), D<\/jats:styled-content>ay\u20092 yielded 0.33\u2009\u00d7\u2009106<\/jats:sup>\/kg CD<\/jats:styled-content>34+ cells, giving a suboptimal total dose. He proceeded to a third PBSCH<\/jats:styled-content> day after plerixafor (0.24\u2009mg\/kg) and G<\/jats:styled-content>\u2010CSF<\/jats:styled-content> (16\u2009\u03bcg\/kg) were given the evening before. A total of 1.79\u2009\u00d7\u2009106<\/jats:sup>\/kg CD<\/jats:styled-content>34+ cells were harvested, giving a total dose of 2.46\u2009\u00d7\u2009106<\/jats:sup>\/kg CD<\/jats:styled-content>34+ cells. After initial neutrophil engraftment on D<\/jats:styled-content>ay\u2009+13, the patient's neutrophils gradually decreased to 0.02\u2009\u00d7\u2009109<\/jats:sup>\/L by D<\/jats:styled-content>ay\u2009+74. A marrow aspirate on D<\/jats:styled-content>ay\u2009+81 was markedly hypocellular. Total white blood cell chimerism was near 100% donor on D<\/jats:styled-content>ays\u2009+32, +74, and +102. Despite chimeric\u2010only engraftment, the patient remains platelet and red blood cell transfusion dependent.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Rescue plerixafor to assist PBSCH<\/jats:styled-content> in healthy allogeneic donors has been effective in terms of CD<\/jats:styled-content>34+ cell number mobilized. It is unclear whether the partial engraftment seen was coincidental or related to a difference in PBSC<\/jats:styled-content> quality.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.12429","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T01:51:23Z","timestamp":1381542683000},"page":"1231-1234","source":"Crossref","is-referenced-by-count":6,"title":["Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest"],"prefix":"10.1111","volume":"54","author":[{"given":"Toby A.","family":"Eyre","sequence":"first","affiliation":[{"name":"Department of Haematology Oxford University Hospitals NHS Trust, Churchill Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals NHS Trust, Churchill Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Peniket","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals NHS Trust, Churchill Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals NHS Trust, Churchill Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Haematology Oxford University Hospitals NHS Trust, Churchill Hospital Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Pawson","sequence":"additional","affiliation":[{"name":"John Radcliffe Hospital, NHS Blood and Transplant Headington Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.11.1797"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705908"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127"},{"key":"e_1_2_6_5_1","volume-title":"Austria\u2010codex","author":"Haberfeld H","year":"2009"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.178"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.226"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.04.004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7209"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.54"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130179"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08547.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214403"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1937"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3592"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2013.03.013"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.09.002"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.07.005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06223.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.12429","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.12429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T15:42:24Z","timestamp":1696002144000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.12429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1111\/trf.12429"],"URL":"https:\/\/doi.org\/10.1111\/trf.12429","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}